Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ESMO 2021 > Lung Cancer > TCR clonality predicts pembrolizumab response in NSCLC

TCR clonality predicts pembrolizumab response in NSCLC

Presented by
Dr Afef Abed, Edith Cowan University, Australia
Conference
ESMO 2021
    Pre-treatment T-cell receptor (TCR) clonality and reduced diversity predicted response rate in non-small cell lung cancer (NSCLC) patients with high PD-L1 treated with pembrolizumab.

    Due to recombination and cellular selection, the immune system is able to produce up to 1011 different TCRs. Increased clonality, reduced diversity, and increased convergence of TCRs have been suggested to reflect clonal expansion of antigen-specific T cells in the tumour microenvironment and to correlate with improved overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Moreover, increased clonality has been linked to increased risk of developing immune related toxicity.

    To further explore the association between TCR repertoire and treatment outcomes, Australian investigators analysed the pre-treatment TCR repertoire in 29 patients with NSCLC (PD-L1 ≥50%) treated with single-agent pembrolizumab and follow-up for at least 18 months. Dr Afef Abed (Edith Cowan University, Australia) presented the results [1].

    Reduced number of unique clones and reduced Shannon diversity was found to be associated with improved ORR to pembrolizumab (P=0.038 and P=0.021, respectively). Moreover, there was a significantly longer PFS in patients with reduced number of unique clones (HR 0.40; P=0.040), reduced Shannon diversity (HR 0.44; P=0.044), reduced Evenness (HR 0.31; P=0.033), and elevated clonality (HR 2.45; P=0.044). None of these parameters were statically significant in relation to OS. Three TCR families (TRBV6-4, TRBV10-2, and TRBV10-3) were observed to occur significantly more frequently among non-responders.

    “So, increased pre-treatment TCR clonality and reduced diversity are associated with improved response rate and PFS, but not OS, in NSCLC patients with high PD-L1 treated with pembrolizumab monotherapy,” concluded Dr Abed. “Further maturation of this cohort will demonstrate whether the circulating pre-treatment TCR repertoire is a prognostic factor for immune checkpoint inhibition.”

    1. Abed A. et al. Clinical value of pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy. Abstract LBA68, ESMO Congress 2021, 16–21 September.

     

    Copyright ©2021 Medicom Medical Publishers



    Posted on